Diskusjon Triggere Porteføljer Aksjonærlister

Targovax (TRVX) Småprat

Biotek
#10383

Ja. Spørsmålet er om det kan komme noe på de første pasientene før det.

#10384

Det hadde ikke gjort noe

#10385

Mesothelioma kommer i Januar, Melanoma cohort 2 mot sommeren, betinget at de rekruteter ferdig iår…

3 Likes
#10386

Mirati la ut nye data for sin KRAS i går:

As of the data cut-off date of October 17, 2019, 22 patients were evaluable for response with at least one radiographic scan:

  • 6/22 evaluable patients achieved a confirmed Complete Response (CR, 1 patient) or Partial Response (PR, 5 patients).
  • 21/22 evaluable patients achieved a CR, PR or stable disease.
  • 4 responding patients have been treated for more than 6 months.

The combination has been well-tolerated and most adverse events (AEs) were Grade 1 or 2.

2 Likes
#10387

Og sammelingnet med TG:

TG01

TG01 is Targovax’s lead RAS immunotherapy product – a neoantigen therapeutic anti-cancer vaccine targeted at the difficult to treat RAS mutations found in over 90% of pancreatic cancer, 50% of colorectal cancer and 20-30% of all cancers. Initially being tested in the clinic in pancreatic cancer, it is hoped that by inducing mutant RAS specific T-cell immune responses in cancer patients with RAS mutations, TG01 will prolong time to cancer progression, increase survival and improve safety and tolerability compared to chemotherapy and other immunotherapies.

The trial enrolled a total of 32 patients, split in two patient cohorts with 19 patients in the 1st cohort and 13 patients in the 2nd cohort. The cohorts receiving different dosing regimens. Totally 94% of patients (30/32) demonstrated mutant RAS-specific immune activation.

Combining the results from the two cohorts, median overall survival (mOS) for all 32 patients was 33.3 months, which is nearly six months better than the mOS of 27.6 months for gemcitabine alone reported in the recent ESPAC4 trial (Neoptolemos JP et al.; The Lancet; 389:1011-1024 (2017)). Median disease free survival (mDFS) from surgery for the 32 patients was 16.1 months, and 19.5 months for the 2nd patient cohort who received the optimized dosing regimen. This DFS outcome is encouraging when compared to historical controls for gemcitabine monotherapy, such as the ESPAC4 and PRODIGE 24 (J Clin Oncol,36, 2018 (suppl; abstr LBA4001)) trials, which reported a median DFS of around 13 months in similar patient populations.

Summarizing the data from the trial:

mDFS (from surgery):

  • Full trial, 32 patients (both cohorts combined): 16.1 months

mOS (from surgery):

  • Full trial, 32 patients (both cohorts combined): 33.3 months

Patients alive two years after surgery:

  • Full trial, 32 patients (both cohorts combined): 72% (23/32)

Patients alive three years after surgery:

  • Full trial, 32 patients (both cohorts combined): 38% (12/32)
2 Likes
#10388

Kreft i bukspyttkjertelen er jo vesentlig vanskeligere, da det ikke har vært fremgang i behandling der på over 40 år. Så vanskelig å sammenligne :slight_smile:

#10389

Det er klart og det gjør vel TG enda mer hot og viktigere.

I segmentet Mirati prøver seg på er jo feks Keytruda en av konkurrentene.

1 Like
#10390

TRVX will also be presenting at the Oncolytic Virotherapy Summit in Boston in December. and will have a TG poster at ESMO-IO in Geneva also in December , DNB Seminar in December.

Jefferies London Healthcare Conference in November, and more will be presented in November 15`th at KOL event in New York.

5 Likes
#10391

Screenshot_20191111-011443_Twitter
Screenshot_20191111-011443_Twitter.jpg1078×1605 607 KB

6 Likes
#10392

Dagens liste:

40
Screenshot 2019-11-11 at 06.48.40.png946×694 71 KB

5 Likes
#10393

Presentation of ONCOS-102 melanoma data at SITC Annual Meeting

5 Likes
#10394

Denne så flott ut!

Advisory boards
• Bristol Myers Squibb (Gamle arbeidsplassen til Jäderberg)
• Immunocore
• Castle Biosciences

Så både AstraZeneca, Bristol Myers Squibb og ikke minst Sotio har interesse/ er involvert i Oncos. Jeg er imponert. Ledelsen har fått til enormt mye på disse årene, folk kan si hva de vil. Mange er nok forbannet på ledelsen for aksjekursutviklingen, men jeg er imponert.
Fantastisk tid vi går i møte framover :slight_smile: Jeg har aldri før eid som så mange trvx-aksjer som jeg har nå :slight_smile:

8 Likes
#10395

Kreften ble forverret med Keytruda. Lav dose Oncos og man ser hvordan den bare forsvinner i løpet av uker.

image
image.jpg1185×565 200 KB

5 Likes
#10396

Kan bli rift om Targovax etterhvert. I løpet av 2020/2021 kan de være i gang med hele 3xpivotal studier.

Skal bli spennende å se om Merck hiver seg med i kampen om Targovax etterhvert.

6 Likes
#10397

Rimelig dødt fra 20 til 50 også

2 Likes
#10398

Synes dette ser enda mer lovende ut enn hva vi ble presentert i sommer.

Det er jo åpenbart flere enn 3 stk som har hatt effekt av behandlingen. Utover 33% ORR så er det jo 2 SD her også, i tillegg til et par pasienter som har hatt effekt på lesjonsnivå, men ble trukket pga av spredning.

Så disse datene levner liten tvil, Oncos funker, og gjør «kalde» svulster «varme» og mottakelig for CPI.

bilde
EB28336A-F6CB-4D50-9247-4E42078686F6.jpeg750×842 216 KB

Og når vi ser på responsrate i 1L Melanoma, så er det jo ingen grunn til å tro at ikke Oncos kan bli benyttet på et mye tidligere sykdomsstadie med dertil tilhørende bedre effekt.

bilde
8DFA65F7-47F0-4790-9641-B47C6B58C3F6.jpeg750×414 165 KB

8 Likes
#10399
01 NORTHERN TRUST GLOBAL SERVICES SE 19.57% 12 405 584
02 RADIUMHOSPITALETS FORSKNINGSSTIFT. 6.98% 4 427 255
03 VERDIPAPIRFONDET NORDEA KAPITAL 2.58% 1 633 448
04 NORDNET BANK AB 2.36% 1 492 988 -6 516
05 NORDNET LIVSFORSIKRING AS 2.31% 1 464 749 2 307
06 THORENDAHL INVEST AS 2.15% 1 365 000
07 VERDIPAPIRFONDET NORDEA AVKASTNING 2.12% 1 344 274
08 DANSKE BANK A/S 1.36% 862 794
09 KLP AKSJENORGE 1.27% 805 275
10 PRIETA AS 1.14% 720 000
11 VERDIPAPIRFONDET NORDEA NORGE PLUS 1.08% 686 203
12 J.P. MORGAN BANK LUXEMBOURG S.A. 1.06% 670 000
13 SUNDT AS 1.03% 650 000
14 KOMMUNAL LANDSPENSJONSKASSE 0.95% 604 464
15 MP PENSJON PK 0.82% 517 786
16 TIMMUNO AS 0.70% 445 118
17 Privat investor 0.66% 416 844
18 MORGAN STANLEY & CO. INTERNATIONAL 0.64% 406 015 1 187
19 Privat investor 0.55% 346 000
20 AVANZA BANK AB 0.53% 335 306 1 030
21 Privat investor 0.51% 325 056
22 ARNE HELLESTØ AS 0.48% 306 302
23 THE BANK OF NEW YORK MELLON SA/NV 0.48% 306 076
24 Privat investor 0.45% 282 500
25 CITIGROUP GLOBAL MARKETS INC. 0.43% 269 603
26 Privat investor 0.42% 265 000
27 BÆKKELAGET HOLDING AS 0.41% 259 000
28 NORDEA BANK ABP 0.41% 258 763
29 Privat investor 0.39% 247 800
30 BARCLAYS CAPITAL SEC. LTD FIRM 0.38% 240 030 220
31 Privat investor 0.35% 224 000
32 NORDANG GEOHOLDING AS 0.34% 215 792
33 Privat investor 0.34% 215 000
34 TROLL HOLDING AS 0.33% 210 000
35 ABAKUS INVEST AS 0.32% 200 000
36 HAWEST HOLDING AS 0.32% 200 000
37 KRISTIAN FALNES AS 0.32% 200 000
38 TOBECH INVEST AS 0.32% 200 000
39 Privat investor 0.32% 200 000
40 Privat investor 0.32% 199 981
41 SAXO BANK A/S 0.30% 191 135 4 971
42 UBS SWITZERLAND AG 0.29% 185 893
43 DANSKE BANK A/S 0.29% 182 041 -73
44 ESPB INVEST AS 0.28% 175 430
45 J.P. MORGAN SECURITIES PLC 0.28% 175 283 INN
46 JPMORGAN CHASE BANK, N.A., LONDON 0.28% 175 195
47 SYVALDSEN AS 0.27% 173 534
48 Privat investor 0.27% 171 328
49 VERDIPAPIRFONDET STOREBRAND 0.27% 170 000
50 Privat investor 0.27% 169 000
51 Øvrige investorer 39.74% 25 190 769 -178 409
4 Likes
#10400

Er det kun non responders eller noen tidligere responders?

#10401

45 J.P. MORGAN SECURITIES PLC 0.28% 175 283 INN

Nice!!

1 Like
#10402

Mange har nok respondert på CPI tidligere, men hadde sluttet å respondere når de kom inn i studien.